Expression characteristic of CXCR1 in different breast tissues and the relevance between its expression and efficacy of neo-adjuvant chemotherapy in breast cancer

• Published in: Oncotarget Vol. 8; no. 30; pp. 48930 - 48937
• Main Authors: Xue, Miao-Qun, Liu, Jun, Sang, Jian-Feng, Su, Lei, Yao, Yong-Zhong
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 25-07-2017
• Subjects: Aged; Biopsy; Breast - metabolism; Breast - pathology; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Follow-Up Studies; Gene Expression; Humans; Immunohistochemistry; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Prognosis; Receptors, Interleukin-8A - genetics; Research Paper; Treatment Outcome; Tumor Burden; breast cancer; neo-adjuvant chemotherapy; breast cancer stem cells; CXCR1; chemokine receptor
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.16893

To investigate chemokine receptor CXCR1 expression characteristic in different breast tissues and analyze the relationship between CXCR1 expression changes in breast cancer tissue and efficacy of neo-adjuvant chemotherapy.
Chemokine receptor CXCR1 was lowly expressed in normal breast tissues and breast fibroadenoma, but highly expressed in breast cancer. It was significantly correlated with pathological stage, tumor cell differentiation, and lymph node metastasis (P < 0.05). After neo-adjuvant chemotherapy, CXCR1 expression in breast cancer tissues decreased. Among these 104 breast cancer patients with different molecular subtypes, the survival rate with Luminal A was the highest, followed by the Luminal B breast cancer, TNBC was the worst.
104 cases with breast carcinoma, 20 cases with normal breast and 20 cases with breast fibroadenoma were included and followed up. Immunohistochemistry was used to detect the expression of CXCR1 in the various tissues. The relationship between the CXCR1 expression changes in breast cancer biopsies and surgical specimens, as well as the efficacy of neo-adjuvant chemotherapy, was analyzed.
Chemokine receptor CXCR1 could be used as an indicator to predict benign or malignant breast disease, and it can even predict the malignancy degree of breast cancer, as well as its invasive ability and prognosis.